TG Therapeutics TGTX Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $700.35M+81.3% | $616.29M+87.3% | $531.9M+101% | $454.07M+31.0% | $386.39M+33.5% | ||
| $118.68M+144% | $100.71M+162% | $77.97M+152% | $59.22M+136% | $48.59M+160% | ||
| $581.67M+72.2% | $515.57M+77.5% | $453.93M+94.1% | $394.85M+22.8% | $337.8M+24.8% | ||
| 83.1%-4.4pp | 83.7%-4.6pp | 85.3%-3.0pp | 87%-5.8pp | 87.4%-6.1pp | ||
| $162.25M+50.3% | $160.22M+69.9% | $142.9M+62.6% | $122.16M+48.1% | $107.93M+16.0% | ||
| $269.92M+58.7% | $232.03M+50.4% | $208.25M+42.2% | $186.85M+36.1% | $170.05M+31.6% | ||
| $218.43M+63.1% | $183.98M+49.7% | $163.43M+39.3% | $145.63M+31.6% | $133.92M-4.0% | ||
| $550.85M+68.7% | $492.96M+71.7% | $429.12M+61.8% | $368.22M+50.4% | $326.57M+35.5% | ||
| $149.5M+150% | $123.32M+194% | $102.78M— | $85.85M— | $59.82M— | ||
| 21.3%+5.9pp | 20%+7.3pp | 19.3%— | 18.9%— | 15.5%— | ||
| $27.64M-3.5% | $26.73M+10.6% | $27.26M+39.6% | $31.37M+153% | $28.63M+137% | ||
| -$27.21M-50.5% | -$15.93M+2.5% | -$15.03M-12.3% | -$19.74M-225% | -$18.08M-168% | ||
| —— | —— | —— | —— | -$3.46M— | ||
| $122.29M+193% | $107.39M+320% | $87.75M— | $66.11M— | $41.74M— | ||
| -$361.67M-14,064% | -$361.85M-16,466% | -$359.72M-75,199% | $5.65M+6,110% | $2.59M+518% | ||
| $461.9M+1,080% | $447.18M+1,812% | $447.47M— | $60.46M— | $39.15M— | ||
| 66%+55.8pp | 72.6%+65.5pp | 84.1%— | 13.3%— | 10.1%— | ||
| $2.87+1,096% | $2.78+1,886% | $2.78— | $0.37— | $0.24— | ||
| $3.22+1,093% | $3.11+1,729% | $3.07— | $0.41— | $0.27— | ||
| 645M+0.3% | 647.7M+3.4% | 646.7M+5.2% | 646.4M+6.0% | 643.2M+8.6% | ||
| 580.9M-0.2% | 583.2M+0.3% | 584.2M+1.1% | 583.8M+1.4% | 581.8M+1.6% | ||
| $18.16M+50.9% | $16.62M+48.9% | $16.14M+48.8% | $13.84M+28.9% | $12.04M-13.3% | ||
| $51.49M+42.5% | $48.05M+53.1% | $44.82M+53.9% | $41.22M+54.6% | $36.14M+36.0% | ||
| $9.58M-9.2% | $10.79M+38.0% | $12.23M+98.9% | $11.63M+83.4% | $10.55M+98.2% | ||
| $144.09M+50.3% | $143.6M+72.7% | $126.75M+64.6% | $108.32M+51.0% | $95.89M+21.1% | ||
| $700.35M+81.3% | $616.29M+87.3% | $531.9M+101% | $454.07M+31.0% | $386.39M+33.5% | ||
| $149.5M+150% | $123.32M+194% | $102.78M— | $85.85M— | $59.82M— | ||
| $149.58M+150% | $123.38M+194% | $102.83M— | $85.89M— | $59.87M— | ||
| $149.58M+150% | $123.38M+194% | $102.83M— | $85.89M— | $59.87M— | ||
| 21.4%+5.9pp | 20%+7.3pp | 19.3%— | 18.9%— | 15.5%— | ||
| $149.5M+150% | $123.32M+194% | $102.78M— | $85.85M— | $59.82M— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is TG Therapeutics's revenue?
- TG Therapeutics (TGTX) generated $700.3M in revenue over the trailing twelve months, up 81.3% year over year.
- Is TG Therapeutics profitable?
- TG Therapeutics reported $461.9M in net income over the trailing twelve months, a 66.0% net margin.
- What are TG Therapeutics's profit margins?
- Gross margin is 83.1% and operating margin is 21.3%, with a 66.0% net margin.
- What is TG Therapeutics's earnings per share?
- TG Therapeutics's diluted EPS over the trailing twelve months is $2.87.
- Where does TG Therapeutics's income statement data come from?
- Every line is extracted from TG Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
